At a glance
- Originator Unknown
- Developer Wyeth
- Class Antihistamines
- Mechanism of Action Histamine H1 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Allergic rhinitis
Most Recent Events
- 31 Aug 1998 No-Development-Reported for Allergic rhinitis in USA (PO)
- 29 Aug 1996 New profile
- 29 Aug 1996 Preclinical development for Allergic rhinitis in USA (PO)